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Introduction
Allergic rhinitis, sinus disease and gastroesophageal reflux (GER) can
contribute to poor asthma control, and should be treated <1, 2, 3, 4>. While
GER is a risk factor for increased severity of chronic rhinosinusitis (CRS) and
asthma, empiric treatment of “silent GER” remains controversial, with current
recommendations focusing on symptomatic GER only <1, 2>. GER has a
higher prevalence in asthmatics (60-80%), when compared to the general
population <1, 4>. It can present like severe asthma in children, and therefore
lead to excessive use of asthma control medications <1>. History of GER is
among the strongest predictive factors for early asthma readmissions<5>.
Impacts of GER on asthma may be overlooked when symptoms do not present
typically.

Case Report
An 11-year-old male with poorly controlled moderate persistent asthma, GER,
recurrent croup, and CRS presents with a persistent barky cough, which began
to worsen around 10 months prior. At the time of presentation, he was on
maximum dosing of inhaled combination mometasone and fomoterol, as well
as montelukast controllers, and had received multiple courses of oral steroids
due to multiple asthma exacerbations and recurrent croup.
Upon chart review the following history was noted:
• Age 7:
• PPI was started despite lack of typical GER symptoms (no
dysphagia, vomiting, epigastric pain), due to poor asthma control and
remote history of GER. He was then referred to Gastroenterology
(GI). Endoscopy at that time revealed esophageal candida infection,
which was treated. No impedance pH probe or esophageal
manometry were performed. HIV and primary immune deficiency
workup were completed due to recurrent pneumonia, croup, sinus
infections, and esophageal candidiasis, which were negative.
• PPI then discontinued as cough was thought to be due to allergic
rhinitis and reactive airway disease. Fexofenadine and intranasal
fluticasone were started, however allergy testing was negative.
• Off PPI, he developed frequent dyspnea, wheezing, recurrent
episodes of croup requiring IV dexamethasone, and increased need
for albuterol and systemic corticosteroids. At that time, speech and
swallow studies, magnified airway x-ray, and esophagram were
normal with no anatomic, or vocal cord abnormalities.
• Low dose PPI was then restarted resulting in only mild improvement
in asthma symptoms and control.
• Age 8:
• Continued poor asthma control, chronic cough and recurrent croup
were noted.

•

• Bronchoscopy at that time revealed edematous, friable, hyperemic
airway mucosa, with negative bacterial and fungal cultures.
Spasmodic croup was thought to be exacerbated by uncontrolled
GER, so omeprazole and ranitidine doses were then maximized.
Age 9-10:
• Asthma remained fairly well controlled for over 1 year, at which
time PPI dosing was reduced, due to concerns of long-term PPI
usage.
• After decreasing PPI dose, over the next 6 months, increased cough,
wheezing, albuterol usage and emergency room visits for asthma
exacerbations were noted.

Upon presentation to our office for consultation, he reported new onset
hoarseness after he stopped PPI, in addition to his chronic cough. He was
once again referred to GI for evaluation. Swallow study was normal. PH
impedance was positive for GERD. Acid suppression was again maximized
with omeprazole and ranitidine, resulting in improvement of asthma control
and resolution of his barky cough.

Lack of typical GER symptoms was also noted in 44% of patients with
uncontrolled asthma and GERD.<8>. Associations between GERD and
increased nasal symptoms including congestion, rhinorrhea, facial pressure
and cough have been reported <2>.
Our patient is an example of atypical GERD presentation in asthma,
highlighting the need to consider GERD, when evaluating treatment regimens
in poorly controlled asthma. More studies are needed on both PPI usage in
uncontrolled asthma with comorbid (both typical and atypically presenting)
and effects of GER control on chronic rhinosinusitis, which may lead to poor
asthma control.
Newer studies have advised caution in long term PPI use, due to increased
cardiovascular risk, decreased mineral absorption, pneumonia etcetera <10>.
Risks versus benefits must be weighed carefully, and long term PPI use should
be reserved for patients with poorly controlled asthma, who demonstrate
evidence of GER and are not responding to traditional control modalities,
including control of allergies and other comorbid conditions. In this case we
argue that even atypical presentations should be considered in poorly
controlled asthmatics, and that if GER is verified, it should be adequately
treated to improve asthma control.

Conclusion
It is well established, that in patients with poor asthma control, comorbid
conditions, such as symptomatic GER should be controlled <1>. Due to these
associations, and as illustrated by this case, atypical GER presentations should
also be considered when treating patients with uncontrolled asthma. Risk and
benefits of poor asthma control, versus long term PPI use in these patients
should be taken into consideration.
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